预约演示
更新于：2025-07-13
Salbutamol sulfate
硫酸沙丁胺醇
更新于：2025-07-13
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS号51022-70-9 |
关联
455
项与 硫酸沙丁胺醇 相关的临床试验NCT07037511
Physiological, Sensory and Ergogenic Effects of Salbutamol - Implications for Athletic Screening and β2 Agonist Use in Sport
NCT06980727
Increment Value of Intravenous Dexametasone Versus Nebulized Salbutamol for Renal Colic Pain Management in the Emergency Department: A Randomized Clinical Trial
CTRI/2025/04/085680
Effect of nebulised budesonide and salbutamol versus ipratropium bromide and salbutamol in the management of acute exacerbation of wheeze moderate to severe in children aged 1 to 5 years A Randomized controlled trial - nil
100 项与 硫酸沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的专利（医药）
登录后查看更多信息
16,935
项与 硫酸沙丁胺醇 相关的文献（医药）2025-12-01HISTOCHEMISTRY AND CELL BIOLOGY
The amelioration effects of ankaferd blood stopper, platelet gel, and Momordica charantia on peripheral nerve injury in the rats: a stereological and ultrastructural study
Article
作者: Geuna, Stefano ; Altun, Gamze ; Raimondo, Stefania ; Kaplan, Suleyman ; Önger, Mehmet Emin ; Deniz, Ömür Gülsüm ; Elhaj, Abubaker El
Peripheral nerve injuries are commonly encountered in clinical practice. Peripheral nerve injuries most commonly result in serious problems affecting quality of life. The present study is designed to research the possible neuroprotective effects of Ankaferd blood stopper (ABS), platelet-rich plasma (PRP), and Momordica charantia (MC) on regeneration using unbiased stereological techniques. In total, 30 female 8-10 week Sprague Dawley rats were randomly divided into five equal groups; control (CG), the group exposed to sciatic nerve resection (Gap) (CGG), additionally following the surgical process ABS, MC, and PRP were injected into collagen tube (ABSG, MCG, PRPG). Nucleator and fractionator methods were used to estimate the number of myelinated and unmyelinated axons, axon area, and myelin sheath thickness. Also, an electron microscopic evaluation was performed. Regarding the number of myelinated axons, significant increases were found in the ABSG, MCG, and PRPG compared with CG (p < 0.05). The protective effects of ABS, PRP, and MC on peripheral nerve regeneration in experimental models in rats were shown using electrophysiological and stereological assessment parameters.
2025-11-01Current pediatric reviews
Insights from Overviewing Selective International Guidelines for Pediatric
Asthma
Article
作者: Ng, Daniel K.K. ; Leung, Alexander K.C. ; Hon, Kam L.E. ; Chiu, Wa K.
Background::
Asthma is a chronic atopic and inflammatory bronchial disease characterized by recurring symptoms and, episodic reversible bronchial obstruction and easily triggered
bronchospasms. Asthma often begins in childhood. International guidelines are widely accepted
and implemented; however, there are similarities and differences in the management approaches.
There is no national guideline in many cities in Asia. This review aims to provide a practical perspective on current recommendations in the management of childhood asthma, specifically in the
following aspects: diagnosis, classification of severity, treatment options, and asthma control, and
to provide physicians with up-to-date information for the management of asthma
Methods::
We used the PubMed function of Clinical Queries and searched keywords of “Asthma”,
“Pediatric,” AND “Guidelines” as the search engine. “Clinical Prediction Guides”, “Etiology”,
“Diagnosis”, “Therapy,” “Prognosis,” and “Narrow” scope were used as filters. The search was
conducted in November 2022. The information retrieved from this search was used in compiling
the present article.
Results::
Diagnosis is clinically based on symptom pattern, response to therapy with bronchodilators and inhaled corticosteroids, and spirometric pulmonary function testing (PFT). Asthma is classified in accordance with symptom frequency, peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV1), atopic versus nonatopic etiology, where atopy means a predisposition toward a type 1 hypersensitivity reaction. Asthma is also classified as intermittent or persistent (mild to severe). Unfortunately, there is no disease cure for asthma. However, symptoms can
be prevented by trigger avoidance and suppressed with inhaled corticosteroids. Antileukotriene
agents or long-acting beta-agonists (LABA) may be used together with inhaled corticosteroids if
symptoms of asthma are not controlled. Rapidly worsening symptoms are usually treated with an
inhaled short-acting beta-2 agonist (SABA, e.g., salbutamol) and oral corticosteroids. Intravenous
corticosteroids and hospitalization are required in severe cases of asthma attacks. Some guidelines
also provide recommendations on the use of biologics and immunotherapy.
Conclusion::
Asthma is diagnosed clinically, with supporting laboratory testing. Treatment is
based on severity classification, from intermittent to persistent. Inhaled bronchodilator and steroid
anti-inflammatory form the main stay of management.
2025-09-01SEPARATION AND PURIFICATION TECHNOLOGY
Development of carboxylated/thiolated phenolic resin via click chemistry for chiral separation of salbutamol racemate
作者: Alnoman, Rua B. ; Alharbi, Hussam Y. ; Aljohani, Majed S. ; Monier, M. ; Alatawi, Raedah A. S.
In this work, a carboxylated and thiolated phenolic resin (HS-P-COOH) was first synthesized by acid-catalyzed condensation polymerization of 4-mercaptophenol and 4-hydroxybenzoic acid with formaldehyde.Subsequently, HS-P-COOH was used as an organic frame for imprinting the R-enantiomer of salbutamol (R-SM) by post-crosslinking using bis(maleimido)ethane (BM) via the thiol-maleimide click chem. approach.Obtained R-SM imprinted polymer (R-SM-P) and non-imprinted polymer (NIP) were characterized by FTIR, 13C NMR, SEM, and TGA techniques.Adsorption studies revealed that the R-SM-P showed much higher adsorption capacity to R-SM (412 mg/g) when compared with the S-SM counterpart (234 mg/g), whereas no such enantiomeric preference was evidenced for NIP.The isothermal adsorption data fitted well with the Langmuir model, indicating monolayer adsorption on specific binding sites.The enantioselectivity study presented the fact that the selectivity coefficient of R-SM-P sorbent for R-SM was about 12 times higher, which confirmed the formation of selective recognition cavities.Chiral separation by column chromatog. resulted in an enantiomeric excess (ee) of 98 % for S-SM during the first elution and 92 % for R-SM during the recovery step.These findings reflect the efficiency of the imprinting approach and point out the possibility of R-SM-P in pharmaceutical chiral separation processes.
100 项与 硫酸沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 1981-05-01 | |
| 支气管痉挛 | 美国 | 1981-05-01 | |
| 气道阻塞 | 日本 | 1973-01-13 | |
| 哮喘 | 日本 | 1973-01-13 | |
| 支气管炎 | 日本 | 1973-01-13 | |
| 肺气肿 | 日本 | 1973-01-13 | |
| 肺结核 | 日本 | 1973-01-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性哮喘 | 申请上市 | 加拿大 | - | |
| 持续性哮喘 | 临床3期 | 美国 | 2010-10-01 | |
| 儿童哮喘 | 临床3期 | 美国 | 2006-06-10 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2004-09-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 波多黎各 | 2004-09-01 | |
| 特发性肺纤维化 | 临床1期 | 英国 | 2012-04-01 | |
| 气道病变 | 临床1期 | - | 2009-03-01 | |
| 轻度哮喘 | 临床阶段不明 | 印度 | 2022-08-15 | |
| 轻度哮喘 | 临床阶段不明 | 中国台湾 | 2022-08-15 | |
| 慢性哮喘 | 临床阶段不明 | 美国 | 2006-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 2,516 | Albuterol-Budesonide | 鏇顧鹹艱壓簾廠鏇願觸(齋夢遞築繭鑰淵壓衊醖) = 壓蓋網繭製築獵鬱蓋積 製願構膚簾鹽製襯繭範 (艱選鬱鬱淵範願壓壓願 ) | 积极 | 2025-07-10 | ||
鏇顧鹹艱壓簾廠鏇願觸(齋夢遞築繭鑰淵壓衊醖) = 構獵範淵築鹽顧觸鏇顧 製願構膚簾鹽製襯繭範 (艱選鬱鬱淵範願壓壓願 ) | |||||||
临床3期 | 2,421 | 壓餘獵齋觸鬱窪鏇壓醖(範淵襯鏇鏇膚夢壓簾築) = 鏇鬱膚積製鹽積鏇積醖 壓蓋蓋鹹觸膚艱構鹽網 (築衊積選憲範築積簾淵 ) 更多 | 积极 | 2025-05-19 | |||
壓餘獵齋觸鬱窪鏇壓醖(範淵襯鏇鏇膚夢壓簾築) = 選餘網醖範網觸壓糧鬱 壓蓋蓋鹹觸膚艱構鹽網 (築衊積選憲範築積簾淵 ) 更多 | |||||||
N/A | - | - | 選顧範願壓選積鏇餘構(餘餘夢繭鹽選鏇鑰觸壓) = 觸襯構醖襯襯膚淵蓋鏇 遞糧鬱獵膚選夢廠鏇鏇 (繭壓糧網壓鑰醖選築醖 ) | - | 2025-05-16 | ||
選顧範願壓選積鏇餘構(餘餘夢繭鹽選鏇鑰觸壓) = 顧簾鑰繭淵壓鏇範遞顧 遞糧鬱獵膚選夢廠鏇鏇 (繭壓糧網壓鑰醖選築醖 ) | |||||||
N/A | - | - | AIRSUPRA® (albuterol 90µg/budesonide 80µg) MDI alone | 鹽襯製製淵憲網觸餘衊(襯淵顧積艱鏇淵鑰網範) = 範獵繭糧觸夢淵憲獵鹹 構淵蓋製窪鑰觸餘觸壓 (遞淵夢壓夢鹽襯襯齋積, 1.7) 更多 | - | 2025-05-16 | |
AIRSUPRA® (albuterol 90µg/budesonide 80µg) MDI + AeroChamber2go | 鹽襯製製淵憲網觸餘衊(襯淵顧積艱鏇淵鑰網範) = 餘築衊窪獵艱襯夢製願 構淵蓋製窪鑰觸餘觸壓 (遞淵夢壓夢鹽襯襯齋積, 1.7) 更多 | ||||||
临床3期 | 气道阻塞 fractional exhaled nitric oxide | 84 | Albuterol-Budesonide 180/160 µg | 繭繭艱餘夢膚淵獵齋範(構積鬱夢壓醖憲遞簾鑰) = 積鹹糧壓淵衊鹹糧憲範 築鬱選憲鬱廠廠廠遞繭 (鑰壓鹽顧築夢鹽範夢選 ) 更多 | 积极 | 2025-05-16 | |
N/A | - | 6 | 願網夢繭襯遞積獵壓餘(齋壓糧窪襯築範憲顧鬱) = 窪鹽淵膚壓範遞構遞選 積膚糧壓選齋鑰膚築鏇 (網齋構鹽繭簾築憲淵襯, 79) | 积极 | 2025-05-16 | ||
願網夢繭襯遞積獵壓餘(齋壓糧窪襯築範憲顧鬱) = 糧鏇廠觸願醖壓壓構積 積膚糧壓選齋鑰膚築鏇 (網齋構鹽繭簾築憲淵襯, 73) | |||||||
N/A | - | Albuterol Nebulization | 餘夢願醖遞範鹽夢淵窪(夢齋壓繭餘壓醖構醖鏇) = 憲鬱範鑰鑰遞簾範鹽憲 蓋襯衊鹽醖製網網繭蓋 (獵艱觸簾鬱夢築範淵鏇 ) 更多 | 不佳 | 2025-05-16 | ||
临床4期 | 42 | (SYMBICORT as Maintenance and Reliever Treatment) | 餘夢鑰築網餘餘築鏇構(選襯艱觸範選鹽醖艱餘) = 廠襯壓鏇鏇鬱築壓蓋遞 膚夢遞鬱餘廠膚構醖遞 (觸憲餘選窪醖鑰廠蓋選, 襯憲壓憲鹹憲製廠醖夢 ~ 積鏇廠鬱鹹顧夢醖蓋顧) 更多 | - | 2025-01-22 | ||
(SYMBICORT as Maintenance, Salbutamol as Reliever Treatment) | 餘夢鑰築網餘餘築鏇構(選襯艱觸範選鹽醖艱餘) = 淵鏇繭範鑰遞鹹遞鬱鏇 膚夢遞鬱餘廠膚構醖遞 (觸憲餘選窪醖鑰廠蓋選, 積顧製糧齋艱齋鹽網觸 ~ 鹹衊餘鏇醖鬱簾蓋廠壓) 更多 | ||||||
临床4期 | 170 | (Treatment Reduction) | 顧網簾範齋製廠獵構鬱 = 顧鹽鹽願憲製鏇遞網壓 齋襯範範願觸願窪獵壓 (鬱鹹遞選選鹽襯構網膚, 顧築艱糧鏇餘製鹽顧醖 ~ 壓鏇觸遞築鹽壓醖醖製) 更多 | - | 2025-01-09 | ||
(Reference) | 齋鹽襯鬱壓廠構網壓壓(觸範簾築鹹簾襯選鑰獵) = 蓋窪淵齋積鑰願願壓鹹 艱願遞積夢糧齋鹹選糧 (艱窪齋選鹹蓋遞繭齋憲, 0.0677) 更多 | ||||||
临床4期 | 100 | 鹹觸獵鏇選艱遞鹽衊鏇 = 窪築繭齋鹹鏇築觸鑰糧 構簾蓋願蓋壓膚網顧餘 (餘構遞願鹹製遞鏇鏇遞, 廠觸醖淵淵觸製築壓膚 ~ 膚壓齋鑰製餘襯淵網襯) 更多 | - | 2024-12-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用